ClinicalTrials.gg

Program

sibeprenlimab

Also written as “Sibeprenlimab”, “Sibeprenlimab 400 mg” and “Sibeprenlimab 400 mg s.c. Q4weeks”.

Its studies are mostly in Glomerulonephritis, IGA · Autoimmune Diseases · Nephrosis, Lipoid, led by Otsuka.

Furthest: phase 3, since Feb 18, 20228 company-led studies, 6 open or runningNext primary completion: Mar 13, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka86 open or runningphase 3since Feb 18, 2022Oct 10, 2018Mar 13, 2027phase 2 · NCT06928142

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2018First study: phase 1 study in Glomerulonephritis, IGAFirst studyNCT03719443 · 51 enrolled · United States
  2. Feb 18, 20222 phase 3 studies in Glomerulonephritis, IGANCT05248659, NCT05248646
  3. Dec 13, 2024Phase 2 study in Glomerulonephritis, IGANCT06740526 · 56 enrolled · United States, Argentina, Canada and more
  4. Mar 25, 2025Phase 2 study in Autoimmune DiseasesNCT06928142 · 83 enrolled · United States, Argentina, Bulgaria and more
  5. Apr 24, 2025Phase 1 study in Healthy Subjects (HS)NCT07105124 · 24 enrolled · China
  6. Aug 13, 2026Phase 3 study in Glomerulonephritis, IGANCT07770815 · 24 planned
  7. Sep 30, 2026Phase 2 study in Nephrosis, LipoidNCT07861113 · 20 planned

Ahead

  1. Mar 13, 2027Primary completion: phase 2 study in Autoimmune DiseasesNCT06928142
  2. Jun 15, 2028Primary completion: phase 2 study in Nephrosis, LipoidNCT07861113
  3. Dec 28, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT06740526
  4. Dec 28, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT05248659

TargetBeta

TNFSF13 →read by rule
“Tumor necrosis factor ligand superfamily member 13 inhibitor”ChEMBL 37, by rule

Other programs on TNFSF13

ProgramCompanyFurthest phaseStudies
zigakibartNovartisphase 36

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07861113Nephrosis, Lipoid2Not yet recruitingJun 15, 202820
NCT07770815Glomerulonephritis, IGA3Not yet recruitingDec 29, 202924
NCT07105124Healthy Subjects (HS) · China1CompletedFeb 15, 202324
NCT06928142Autoimmune Diseases · United States, Argentina, Bulgaria and more2Active, not recruitingMar 13, 202783
NCT06740526Glomerulonephritis, IGA · United States, Argentina, Canada and more2Active, not recruitingDec 28, 202856
NCT05248659Glomerulonephritis, IGA · United States, Argentina, Australia and more3By invitationDec 28, 2028600
NCT05248646Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingMay 13, 2026530
NCT03719443Glomerulonephritis, IGA · United States1CompletedAug 10, 201951

How it is read

Names in the registry

  • “Sibeprenlimab”, 5 entries
  • “Sibeprenlimab 400 mg”, 1 entry
  • “Sibeprenlimab 400 mg s.c. Q4weeks”, 1 entry
  • “VIS649”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.